Therapeutic diabetes drugs, particularly DPP4 inhibitors and/or GLP-1 analogs, may beneficially alter the pathophysiology of PD, reduce the incidence of PD, and improve the functioning of PD patients (Brauer et al., 2020; Wang et al., 2020). This evidence concerns the gene GCG and Parkinson disease.